Efficacy of ursodeoxycholic acid combined with Tongdan Decoction (通胆汤) on immunological indices and histopathological changes in primary biliary cirrhosis patients

Guang-dong Tong; Hai-hong Tang; Chun-shan Wei; Ying-jie Chen; Jin-song He; Xiao-zhou Zhou; Ying-jun Zheng; Da-qiao Zhou

doi:10.1007/s11655-0112-0962-9

Your Location：

Home >

Browse articles >

Efficacy of ursodeoxycholic acid combined with Tongdan Decoction (通胆汤) on immunological indices and histopathological changes in primary biliary cirrhosis patients

Updated：2021-08-27

- Efficacy of ursodeoxycholic acid combined with Tongdan Decoction (通胆汤) on immunological indices and histopathological changes in primary biliary cirrhosis patients
- Chinese Journal of Integrative Medicine Vol. 18, Issue 1, Pages: 16-22(2012)
- Affiliations：
  
  Department of Liver Disease, Shenzhen Hospital Affiliated to Guangzhou University of Chinese Medicine,Guangdong Province,Shenzhen,China
- Author bio：
- Funds：
- DOI：10.1007/s11655-0112-0962-9
  CLC：
- Published：2012，
  
  Published Online：10 January 2012，
Scan for full text
Tong, Gd., Tang, Hh., Wei, Cs. et al. Efficacy of ursodeoxycholic acid combined with Tongdan Decoction (通胆汤) on immunological indices and histopathological changes in primary biliary cirrhosis patients., Chin. J. Integr. Med. 18, 16–22 (2012). https://doi.org/10.1007/s11655-0112-0962-9

Guang-dong Tong, Hai-hong Tang, Chun-shan Wei, et al. Efficacy of ursodeoxycholic acid combined with Tongdan Decoction (通胆汤) on immunological indices and histopathological changes in primary biliary cirrhosis patients. [J]. Chinese Journal of Integrative Medicine 18(1):16-22(2012)
Tong, Gd., Tang, Hh., Wei, Cs. et al. Efficacy of ursodeoxycholic acid combined with Tongdan Decoction (通胆汤) on immunological indices and histopathological changes in primary biliary cirrhosis patients., Chin. J. Integr. Med. 18, 16–22 (2012). https://doi.org/10.1007/s11655-0112-0962-9 DOI：

Guang-dong Tong, Hai-hong Tang, Chun-shan Wei, et al. Efficacy of ursodeoxycholic acid combined with Tongdan Decoction (通胆汤) on immunological indices and histopathological changes in primary biliary cirrhosis patients. [J]. Chinese Journal of Integrative Medicine 18(1):16-22(2012) DOI： 10.1007/s11655-0112-0962-9.

摘要

To observe the efficacy of ursodeoxycholic acid (UDCA) combined with Tongdan: Decoction (通胆汤) on immunological indices and histopathological changes in patients with primary biliary cirrhosis (PBC) of IIor III histological stage. Sixty PBC patients were assigned randomly and equally: to the control group treated with UDCA alone and the treatment group treated with UDCA combined with Tongdan Decoction. The immunological indices and histopathological changes were detected before and after 24-week treatment

and the follow-up lasted for 1–3 years. After 24-week treatment

CD4+CD28− in the peripheral blood was lowered and CD4+CD25+ was increased in both groups

and better effect was shown in the treatment group (P<0.01). The levels of IgM

IgG

and IgA decreased markedly after 96-week treatment in the treatment group (P< 0.05

P< 0.01)

while in the control group

only the latter two showed significant decrease after 148 week (all P<0.05). At the end of the 3-year follow-up

the medians of histopathological <inflammation grading and fibrosis staging declined to a lower rank

and the effect on inflammation was superior in the treatment group to the control group shown by non-parameters Wilcoxon paired symbols test ( Z=2.761

P=0.006). Combined therapy of Tongdan Decoction and UDCA showed a better therapeutic effect: than UDCA monotherapy on PBC

especially in improving immunological indices and histopathological hepatic changes.

Abstract

and the follow-up lasted for 1–3 years. After 24-week treatment

CD4+CD28− in the peripheral blood was lowered and CD4+CD25+ was increased in both groups

and better effect was shown in the treatment group (P<0.01). The levels of IgM

IgG

and IgA decreased markedly after 96-week treatment in the treatment group (P< 0.05

P< 0.01)

while in the control group

only the latter two showed significant decrease after 148 week (all P<0.05). At the end of the 3-year follow-up

the medians of histopathological <inflammation grading and fibrosis staging declined to a lower rank

and the effect on inflammation was superior in the treatment group to the control group shown by non-parameters Wilcoxon paired symbols test ( Z=2.761

P=0.006). Combined therapy of Tongdan Decoction and UDCA showed a better therapeutic effect: than UDCA monotherapy on PBC

especially in improving immunological indices and histopathological hepatic changes.

关键词

ursodeoxycholic acidPrimary Biliary CirrhosisimmunologypathologyChinese Medicinecombined treatment

Keywords

ursodeoxycholic acidPrimary Biliary CirrhosisimmunologypathologyChinese Medicinecombined treatment

references

Charatcharoenwitthaya P, Lindor KD. Current concepts in the pathogenesis of primary biliary cirrhosis. Ann Hepatol 2005;4:161–175.

Leuschner U. Primary biliary cirrhosis—presentation and diagnosis. Clin Liver Dis 2003;7:741–758.

Dahlan Y, Smith L, Simmonds D, Jewell LD, Wanless I, Heathcote EJ, Bain VG. Pediatric-onset primary biliary cirrhosis. Gastroenterology 2003;125:1476–1479.

Kumagi T, Heathcote EJ. Primary biliary cirrhosis. Orphanet J Rare Dis 2008;3:1.

Zhang F, Jia J, Wang B, Qian L, Yin S, Wang Y, et al. Clinical characteristics of primary biliary cirrhosis: a report of 45 cases. Chin J Int Med (Chin) 2002;41:163–167.

Yao GB. A prospective study of primary biliary cirrhosis in Chinese patients. Chin Hepatol (Chin) 2002;7:146–149.

Siegel JL, Jorgensen R, Angulo P, Lindor KD. Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis. J Clin Gastroenterol 2003;37:183–185.

Lindor K. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. N Engl J Med 2007;357:1524–1529.

Pares A, Rodes J. Treatment of primary biliary cirrhosis. Minerva Gastroenterol Dietol 2000;46:165–174.

Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991;324:1548–1554.

Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, et al. The canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994;19:1149–1156.

Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999;354:1053–1060.

Poupon RE, Lindor KD, Pares A, Chazouilleres O, Poupon R, Heathcote EJ. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003;39:12–16.

ter Borg PC, Schalm SW, Hansen BE, van Buuren HR. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10yr cohort study involving 297 patients. Am J Gastroenterol 2006;101:2044–2050.

Ludwig J, Dickson ER, Mcdonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978;379:103–112.

Qiu DK, Ma X. Bases and clinics of autoimmune liver diseases. Shanghai: Shanghai Scientific and Technical Publishers (Chin); 2006.

Wang D, Zhang H, Liang J, Gu Z, Zhou Q, Fan X, et al. CD4+ CD25+ but not CD4+ Foxp3+ T cells as a regulatory subset in primary biliary cirrhosis. Cell Mol Immunol 2010;7:485–490.

Zhang Y, Chen WZ, Shi JM. Effect of estrogen receptor alpha gene polymorphism on the variations of T lymphocyte subsets and its related cell factors in female patients with primary cholestasis cirrhosis. Chin J Hepatol (Chin) 2010;18:740–744.

Su CZ, Dong HH, Zhong R. Treatment of primary biliary cirrhosis with Chinese medicine. J China Tradit Chin Med Inform (Chin) 2011;3:140.

Tang H, Chen Y, Tong G, Zhou D, He J, Zhou X, Zheng Y. Efficacy of ursodeoxycholic acid combined with Tongdan Decoction in treatment of patients with primary biliary cirrhosis. World Chin J Digestol (Chin) 2008;16:1417–1424.

Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 2000;31:1005–1013.

Chinese Medical Association. Prevention and solution of viral hepatitis. Chin J Hepatol (Chin) 2000;8:324.

Chen G, Li L, Gao J, Li F, Li B. Primary biliary cirrhosis: an analysis of 153 cases. Chin Med J (Chin) 2002;82:1625–1628.

Zhao P, Zhu L, Yao DK. Progress in the study of recurrent primary biliary cirrhosis after orthotopic liver transplantation. Chin J Hepatol (Chin) 2007;15:396–398.

Klein R, Pointner H, Zilly W, Glassner-Bittner B, Breuer N, Garbe W, et al. Antimitochondrial antibody profiles in primary biliary cirrhosis distinguish at early stages between a benign and a progressive course: a prospective study on 200 patients followed for 10 years. Liver 1997;17:119–128.

Klein R, Huizenga JR, Gips CH, Berg PA. Antimitochondrial antibody profiles in patients with primary biliary cirrhosis before orthotopic liver transplantation and titres of antimitochondrial antibody-subtypes after transplantation. J Hepatol 1994;20:181–189.

Duan WJ, Jia JD, Diagnosis and Management of Primary Biliary Cirrhosis. Chin J Gastroenterol (Chin) 2009;14:209–213.

Bernuzzi F, Fenoglio D, Battaglia F, Fravega M, Gershwin ME, Indiveri F, et al. Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis. J Autoimmun 2010;35:176–180.

Jiang YF, Jin QL, Li WY, Xu HN, Niu JQ. An analysis of CD4+CD25+CD127low/− regulatory T cells and their immunological functions in patients with primary biliary cirrhosis. Chin J Hepatol (Chin) 2008;16:620–621.

FULL TEXT LINK

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

A case of autoimmune hepatitis and primary biliary cirrhosis overlap syndrome treated with chinese herbs

Effect of Aike Mixture (艾可合剂) on the inflammatory infiltration in patients with chronic prostatitis type III A

Future view and development of immunology: Exploring the immunology based on Chinese medicine and culture

Cost-effectiveness analysis of combined Chinese medicine and Western medicine for ischemic stroke patients

Objective tongue inspection on 142 liver cancer patients with damp-heat syndrome

Related Author

No data

Related Institution

Liver Failure Therapy and Research Center, Hospital

Radiology Department

Emergency Department

People’s Hospital Affiliated to Fujian College of Traditional Chinese Medicine

The Second Fujian Provincial People’s Hospital

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰